Oxford Biomedica PLC Total Voting Rights (9857X)
May 02 2023 - 2:00AM
UK Regulatory
TIDMOXB
RNS Number : 9857X
Oxford Biomedica PLC
02 May 2023
Oxford Biomedica
Total Voting Rights
Oxford, UK - 2 May 2023: Oxford Biomedica plc (LSE:OXB) ("Oxford
Biomedica" or "the Company"), a quality and innovation-led viral
vector CDMO, today announces that in accordance with the FCA's
Disclosure Guidance and Transparency Rule 5.6.1R, the Company's
issued share capital as at the close of business on 28 April 2023
consisted of 96,460,891 ordinary shares of 50 pence each ("Ordinary
Shares"). There are no Ordinary Shares held in treasury.
Accordingly, the total number of voting rights in Oxford
Biomedica plc at the date of this notice is 96,460,891.
The above figure ( 96,460,891) may be used by shareholders as
the denominator for the calculations by which they will determine
if they are required to notify their interest in, or a change to
their interest in, Oxford Biomedica plc under the FCA's Disclosure
Guidance and Transparency Rules.
-Ends-
For further information, please
contact:
Oxford Biomedica plc: Tel: +44 (0)1865 783 000
Natalie Walter, Company Secretary
About Oxford Biomedica
Oxford Biomedica (LSE: OXB) is a quality and innovation-led
viral vector CDMO with a mission to enable its clients to deliver
life changing therapies to patients around the world.
One of the original pioneers in cell and gene therapy, the
Company has more than 25 years of experience in viral vectors; the
driving force behind the majority of gene therapies. The Company
collaborates with some of the world's most innovative
pharmaceutical and biotechnology companies, providing viral vector
development and manufacturing expertise in lentivirus,
adeno-associated virus (AAV) and adenoviral vectors. Oxford
Biomedica's world-class capabilities span from early-stage
development to commercialisation. These capabilities are supported
by robust quality-assurance systems, analytical methods and depth
of regulatory expertise.
Oxford Biomedica, a FTSE4Good constituent, is headquartered in
Oxford, UK. It has locations across Oxfordshire, UK and a US-based
subsidiary, Oxford Biomedica Solutions, based near Boston, MA, US.
Learn more at www.oxb.com, www.oxbsolutions.com, and follow us on
LinkedIn, Twitter and YouTube.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
TVREAESFELEDEAA
(END) Dow Jones Newswires
May 02, 2023 02:00 ET (06:00 GMT)
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Apr 2024 to May 2024
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From May 2023 to May 2024